Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Bayer Initiates a Phase III Study in Heart Failure Patients

By Zacks Investment ResearchStock MarketsJun 15, 2020 10:00PM ET
www.investing.com/analysis/bayer-initiates-a-phase-iii-study-in-heart-failure-patients-200527869
Bayer Initiates a Phase III Study in Heart Failure Patients
By Zacks Investment Research   |  Jun 15, 2020 10:00PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Bayer (OTC:BAYRY) Aktiengesellschaft BAYRY announced the initiation of FINEARTS-HF, a placebo-controlled phase III study on finerenone. The study will investigate finerenone compared to placebo in more than 5,500 symptomatic heart failure patients with a left ventricular ejection fraction of ≥40%.

The primary objective of the study is to demonstrate the superiority of finerenone over placebo in reducing the rate of the composite endpoint of cardiovascular death and total (first and recurrent) heart failure (HF) events. Patients will be randomized to receive either finerenone once daily (titrated up to 40 mg) or placebo. The FINEARTS-HF study will assess whether the candidateleads to a reduction in the risk of cardiovascular death and other heart failure events in patients.

Finerenone (BAY 94-8862) is an investigational, non-steroidal, selective mineralocorticoid receptor antagonist that has been shown to block the harmful effects of the over-activated mineralocorticoid receptor (MR) system. MR overactivation is a major driver of heart and kidney damage. It is the first non-steroidal MR antagonist that is being developed in heart failure with preserved ejection fraction.

Shares of the company have lost 6.8% year to date compared with the industry’s decline of 5.3%.

The initiation of the FINEARTS-HF study is based onthe robust phase II studies ARTS-HF and ARTS-DN, which investigated the efficacy and safety of finerenone in patients with heart failure and chronic kidney disease (CKD), respectively.

Finerenone is already being investigated in large, long-term outcome studies in patients with CKDand type II diabetes (T2D).

We remind investors that, earlier this month, the company submitted regulatory applications seeking the approval of pipeline candidate, vericiguat, in the EU and Japan. Vericiguat is an experimental once-daily, first-in-class soluble guanylate cyclase (sGC)-stimulator being developed to treat patients with symptomatic chronic heart failure with an ejection fraction less than 45%, who have had a previous worsening heart failure event (defined as heart failure hospitalization or receiving an intravenous diuretic for heart failure without hospitalization), in combination with available heart failure therapies.

Bayer is developing the candidate in collaboration with Merck MRK.

Novartis’ NVS Entresto is approved to reduce the risk of death and hospitalization in people with certain types of long-lasting (chronic) heart failure.

Bayer is undertaking several initiatives to strengthen its position across portfolios, enhance efficiency and accelerate structural measures, including the decision to exit the Animal Health business unit. The company had earlier announced the divestment of its Animal Health business to Elanco ELAN. Meanwhile, the Monsanto (NYSE:MON) acquisition in 2018 has strengthened Bayer's position.

Zacks Rank

Bayer currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Just Released: Zacks’ 7 Best Stocks for Today

Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.1% per year. These 7 were selected because of their superior potential for immediate breakout.

See these time-sensitive tickers now >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Merck Co., Inc. (MRK): Free Stock Analysis Report

Novartis AG (NVS): Free Stock Analysis Report

Bayer Aktiengesellschaft (BAYRY): Free Stock Analysis Report

Elanco Animal Health Incorporated (NYSE:ELAN): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research
Bayer Initiates a Phase III Study in Heart Failure Patients
 

Related Articles

Bayer Initiates a Phase III Study in Heart Failure Patients

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email